Krystal Biotech had its Relative Strength (RS) Rating upgraded from 71 to 81 Monday.
Risk Management In The Stock Market: How Much Money To Invest Now
This proprietary rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks matches up against that of all other stocks.
Decades of market research shows that the market's biggest winners tend to have an 80 or higher RS Rating as they begin their biggest climbs.
Krystal Biotech is not currently near a potential buying area. See if the stock goes on to build a sound pattern that could spark a new run.
While the company's top line growth fell last quarter from 879% to 116%, the bottom line grew 407%, up from 0% in the previous report. The company is expected to report its latest performance numbers on or around May 6.
The company holds the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
